Cyclotides as immunosuppressive agents

• US 10,159,710 B2
• Filed: 08/23/2016
• Issued: 12/25/2018
• Est. Priority Date: 12/22/2011
• Status: Active Grant

• Current Assignee: Medizinische Uni Wien, Universitätsklinikum Freiburg
• Original Assignee: Medizinische Uni Wien, Universitätsklinikum Freiburg
• Inventors: Gruber, Christian Werner, Gruendemann, Carsten
• Primary Examiner(s): Lieb, Jeanette M
• Application Number:
  US15/244,244
• Publication Number:
  US 20160367626A1
• Time in Patent Office: 854 Days
• Field of Search: None
• CPC Class Codes: A61K 38/12 Cyclic peptides , e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 38/16 Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof enzyme inhibitors A61K38/005
• CPC Class Codes: A61K 38/168 from plants
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 51/08 Peptides, e.g. proteins , carriers being peptides, polyamino acids, proteins
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C07K 14/00 Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• CPC Class Codes: C07K 14/415 from plants
• CPC Class Codes: G01N 33/5023 on expression patterns
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to a pharmaceutical composition comprising a cyclotide for use in immune suppression as well as to a method for immune suppression comprising the step of administering an effective amount of a pharmaceutical composition comprising such a cyclotide to a subject in need thereof. The present invention also relates to a pharmaceutical composition comprising a cyclotide for use in treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation. Likewise, the present invention also relates to a method for treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation. The present invention further relates to a method of screening for and/or selecting an immunosuppressive cyclotide or a mutation which results in a mutated cyclotide having an induced or enhanced immunosuppressive activity. The present invention further relates to a method of producing an immunosuppressive cyclotide or an immunosuppressive pharmaceutical composition. The present invention further relates to a mutated cyclotide having immunosuppressive activity and a pharmaceutical composition comprising the same.

Claims

1. A method for immunosuppression, the method comprising administering an effective amount of a non-grafted kalata B cyclotide or mutants or variants thereof to a subject in need thereof, wherein said cyclotide comprises a head-to tail cyclized peptide, wherein said head-to tail cyclized peptide comprises six conserved cysteine residues capable to form three disulfide bonds arranged in a cyclic cystine-knot (CCK) motif.

2. The method of claim 1, wherein said cyclotide does not include another therapeutic peptide.

3. The method of claim 1, wherein said cyclotide comprises an amino acid sequence of formula II;

wherein formula II comprises;

4. The method of claim 1, wherein said cyclotide comprises a cyclic backbone having the structure of formula I, wherein formula I comprises the amino acid sequence:

Cyclo(C[X₁ . . . Xa]C[XI1 . . . XIb]C[XII1 . . . XIIc]C[XIII1 . . . XIIId]C[XIV1 . . . XIVe]C[XV1 . . . XVf]);

wherein C is cysteine;

wherein each of [X1 . . . Xa], [XI1 . . . XIb], [XII1 . . . XIIc], [XIII1 . . . XIIId], [XIV1 . . . XIVe], and [XV1 . . . XVf] represents one or more amino acid residues, wherein each one or more amino acid residues within or between the sequence residues may be the same or different; and

wherein a, b, c, d, e, and f represent the number of amino acid residues in each respective sequence and each of a to f may be the same or different and range from 1 to about 20.

5. The method of claim 1, wherein said cyclotide has an anti-proliferative effect on (an) immune cell(s) and/or suppresses/reduces the effector function(s) of (an) immune cell(s).

6. The method of claim 4, wherein a is 3 to 6, b is 4 to 8, c is 3 to 10, d is 1, e is 4 to 8, and/or f is 5 to 13.

7. The method of claim 1, wherein said cyclotide comprises:

an amino acid sequence selected from the group consisting of SEQ ID NOs;

1, 2, and 3;

(ii) an amino acid sequence encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOs;

11, 12, 15, and 16;

(iii) an amino acid sequence encoded by a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ID NOs;

1, 2, and/or

(iv) an amino acid sequence that is at least 90% identical to any amino acid sequence of (i) to (iii).

8. The method of claim 1, wherein said cyclotide comprises kalata B1 or kalata B2.

9. The method of claim 1, wherein said cyclotide is administered so that cytostatic but no cytotoxic activity occurs.

10. The method of claim 1, wherein said cyclotide is administered in an amount to reach a serum concentration in the range of 1 to 50 μ

M.

11. The method of claim 1, wherein said pharmaceutical composition further comprises one or more additional immunosuppressants.

12. The method of claim 11, wherein said additional immunosuppressant comprises Cyclosporine A, Muromonab-CD3 or Basiliximab.

13. The method of claim 1, for the treatment of a subject suffering from a disorder selected from the group consisting of an autoimmune disorder, a hypersensitivity disorder, and a lymphocyte-mediated inflammation.

14. The method of claim 13, wherein said autoimmune disorder is selected from the group consisting of Multiple Sclerosis, Psoriasis, Systemic Lupus Erythematosus, Sojö

gren'"'"'s syndrome, Rheumatoid Arthritis, Idiopathic Thrombocytopenic Purpura, Diabetes, Vasculitis, and Crohn'"'"'s disease.

15. The method of claim 13, wherein said lymphocyte-mediated inflammation comprises a T cell-mediated inflammation.

16. The method of claim 13, wherein said lymphocyte-mediated inflammation comprises keratoconjunctivitis sicca or dry eye syndrome (DES).

17. The method of claim 1, wherein the amino acid sequence of said cyclotide is radio-labelled, fluorescence-labelled or biotin-labelled.

18. The method of claim 1, wherein:

the proliferation of (an) immune cell(s);

the effector function(s) of (an) immune cell(s);

the degranulation/cytotoxicity of (an) immune cell(s);

the expression of a cytokine surface receptor on (an) immune cell(s);

the proliferation of (primary) activated lymphocytes;

the proliferation of peripheral blood mononuclear cells (PBMC);

secretion/production of IL-2, IFN-gamma and/or TNF-alpha;

degranulation/cytotoxicity of CD107a+ CD8+ PBMCs; and

/or

expression of IL-2 surface receptor CD25 is/are suppressed.

19. The method of claim 1, wherein said cyclotide

suppresses/reduces secretion/production of IL-2, IFN-gamma and/or TNF-alpha;

suppresses/reduces degranulation/cytotoxicity of CD107a+ CD8+ PBMCs; and

/or

suppresses/reduces expression of IL-2 surface receptor CD25.

20. The method of claim 1, wherein the anti-proliferative effect or suppression/reduction is mediated in an IL-2-, IFN-gamma- and/or TNF-alpha-depending manner and/or can be antagonized by IL-2.

21. The method of claim 1 comprising oral administration.

22. The method of claim 1, wherein said cyclotide is administered in an amount to reach a serum concentration in the range of 3 to 10 μ

M.

23. The method of claim 1, wherein said cyclotide is administered in an amount to reach a serum concentration in the range of 4 to 9 μ

M.

24. The method of claim 1, wherein said cyclotide is administered in an amount to reach a serum concentration in the range of 5 to 9 μ

M.